NL301202I1 - Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline - Google Patents
Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix cholineInfo
- Publication number
- NL301202I1 NL301202I1 NL301202C NL301202C NL301202I1 NL 301202 I1 NL301202 I1 NL 301202I1 NL 301202 C NL301202 C NL 301202C NL 301202 C NL301202 C NL 301202C NL 301202 I1 NL301202 I1 NL 301202I1
- Authority
- NL
- Netherlands
- Prior art keywords
- linzagolix
- choline
- pharmaceutically acceptable
- acceptable salt
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005304395 | 2005-10-19 | ||
| JP2006147019 | 2006-05-26 | ||
| PCT/JP2006/320681 WO2007046392A1 (ja) | 2005-10-19 | 2006-10-17 | 縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL301202I1 true NL301202I1 (nl) | 2022-11-09 |
| NL301202I2 NL301202I2 (nl) | 2023-01-24 |
Family
ID=37962485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL301202C NL301202I2 (nl) | 2005-10-19 | 2022-11-01 | Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9040693B2 (nl) |
| EP (1) | EP1939204B3 (nl) |
| JP (2) | JP4955566B2 (nl) |
| KR (1) | KR101384132B1 (nl) |
| AU (1) | AU2006305271B2 (nl) |
| BR (1) | BRPI0617436B8 (nl) |
| CA (1) | CA2624492C (nl) |
| CY (1) | CY1113898T1 (nl) |
| DK (1) | DK1939204T6 (nl) |
| ES (1) | ES2398917T7 (nl) |
| HK (1) | HK1125110A1 (nl) |
| IL (1) | IL190754A (nl) |
| NL (1) | NL301202I2 (nl) |
| NO (1) | NO343185B1 (nl) |
| NZ (1) | NZ567300A (nl) |
| PL (1) | PL1939204T6 (nl) |
| PT (1) | PT1939204E (nl) |
| RU (1) | RU2418803C2 (nl) |
| SI (1) | SI1939204T1 (nl) |
| TW (1) | TWI400074B (nl) |
| WO (1) | WO2007046392A1 (nl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008124614A1 (en) * | 2007-04-06 | 2008-10-16 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| PE20090044A1 (es) * | 2007-04-06 | 2009-01-23 | Neurocrine Biosciences Inc | Antagonistas del receptor de la hormona liberadora de gonadotropina y procedimientos relacionados con los mismos |
| CA2682519A1 (en) * | 2007-04-18 | 2008-11-06 | Kissei Pharmaceutical Co., Ltd. | Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes |
| CA2682400A1 (en) * | 2007-04-18 | 2008-11-06 | Kissei Pharmaceutical Co., Ltd. | Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes |
| RU2557237C2 (ru) | 2010-02-10 | 2015-07-20 | Киссеи Фармасьютикал Ко., Лтд. | Соль конденсированного гетероциклического производного и его кристаллы |
| CA2882879A1 (en) | 2012-08-24 | 2014-02-27 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP6268093B2 (ja) * | 2012-09-14 | 2018-01-24 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
| WO2015103508A1 (en) * | 2014-01-06 | 2015-07-09 | Bristol-Myers Squibb Company | CARBOCYCLIC SULFONE RORγ MODULATORS |
| MX2019001596A (es) * | 2016-08-08 | 2019-09-19 | Kissei Pharmaceutical | Uso y dosificacion de agentes terapeuticos para endometriosis. |
| UA127018C2 (uk) * | 2017-01-31 | 2023-03-15 | Веру Інк. | КОМПОЗИЦІЇ ТА СПОСОБИ ТРИВАЛОГО ВИВІЛЬНЕННЯ АНТАГОНІСТІВ ГОНАДОТРОПІН-ВИВІЛЬНЯЮЧОГО ГОРМОНА (GnRH) |
| AU2018280741B2 (en) | 2017-06-05 | 2023-12-21 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| MA49256A (fr) * | 2017-06-05 | 2021-05-26 | ObsEva SA | Schémas posologiques comprenant un antagoniste de l'hormone de libération des gonadotrophines pour le traitement de l'endométriose |
| CN112105608B (zh) * | 2018-01-30 | 2023-07-14 | 因赛特公司 | 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法 |
| MA54058A (fr) | 2018-10-29 | 2021-09-08 | ObsEva SA | Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale |
| KR20210100623A (ko) | 2018-11-07 | 2021-08-17 | 옵스에파 에스에이 | 에스트로겐-의존성 장애의 치료를 위한 조성물 및 방법 |
| CA3150089A1 (en) * | 2019-08-08 | 2021-02-11 | ObsEva S.A. | Gnrh antagonists for the treatment of estrogen-dependent disorders |
| CA3148939A1 (en) | 2019-08-08 | 2021-02-11 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
| WO2022179469A1 (zh) * | 2021-02-23 | 2022-09-01 | 南京明德新药研发有限公司 | 噻吩并嘧啶二酮类化合物及其应用 |
| EP4299569A1 (en) * | 2021-02-23 | 2024-01-03 | Soter Biopharma Pte. Ltd. | Fused polycyclic substituted 5-carboxylic acid thienopyrimidine dione compound and use thereof |
| WO2024037532A1 (zh) * | 2022-08-16 | 2024-02-22 | 深圳市康哲生物科技有限公司 | 一种噻吩并嘧啶酮衍生物的盐型及晶型 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69622677T2 (de) * | 1995-12-08 | 2003-03-20 | Takeda Chemical Industries Ltd | Hemmer der Prolaktinsynthese |
| CA2250908C (en) * | 1996-04-30 | 2012-03-13 | Takeda Chemical Industries, Ltd. | Combined use of gnrh agonist and antagonist |
| JP2000511532A (ja) * | 1996-05-20 | 2000-09-05 | メルク エンド カンパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモンのアンタゴニスト |
| GB0124627D0 (en) * | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
| US20070135454A1 (en) | 2003-11-14 | 2007-06-14 | Tracy Bayliss | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) |
| EP1697381A4 (en) | 2003-12-19 | 2009-03-11 | Merck & Co Inc | INHIBITORS OF MITOTIC KINESINES |
| WO2006083005A1 (ja) * | 2005-02-03 | 2006-08-10 | Takeda Pharmaceutical Company Limited | 縮合ピリミジン誘導体およびその用途 |
-
2006
- 2006-10-17 SI SI200631557T patent/SI1939204T1/sl unknown
- 2006-10-17 NZ NZ567300A patent/NZ567300A/en unknown
- 2006-10-17 ES ES06811925T patent/ES2398917T7/es active Active
- 2006-10-17 RU RU2008119462/04A patent/RU2418803C2/ru active
- 2006-10-17 CA CA2624492A patent/CA2624492C/en active Active
- 2006-10-17 DK DK06811925.4T patent/DK1939204T6/da active
- 2006-10-17 BR BRPI0617436A patent/BRPI0617436B8/pt active IP Right Grant
- 2006-10-17 AU AU2006305271A patent/AU2006305271B2/en active Active
- 2006-10-17 PL PL06811925.4T patent/PL1939204T6/pl unknown
- 2006-10-17 PT PT68119254T patent/PT1939204E/pt unknown
- 2006-10-17 US US12/089,674 patent/US9040693B2/en active Active
- 2006-10-17 WO PCT/JP2006/320681 patent/WO2007046392A1/ja active Application Filing
- 2006-10-17 EP EP06811925.4A patent/EP1939204B3/en active Active
- 2006-10-17 KR KR1020087010997A patent/KR101384132B1/ko active IP Right Grant
- 2006-10-17 JP JP2007540993A patent/JP4955566B2/ja active Active
- 2006-10-19 TW TW095138520A patent/TWI400074B/zh active
-
2008
- 2008-04-09 IL IL190754A patent/IL190754A/en active IP Right Grant
- 2008-05-19 NO NO20082249A patent/NO343185B1/no unknown
-
2009
- 2009-04-09 HK HK09103380.3A patent/HK1125110A1/xx unknown
-
2012
- 2012-01-19 JP JP2012008680A patent/JP5319797B2/ja active Active
-
2013
- 2013-04-02 CY CY20131100276T patent/CY1113898T1/el unknown
-
2022
- 2022-11-01 NL NL301202C patent/NL301202I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301202I2 (nl) | Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline | |
| NL301106I1 (nl) | Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301256I2 (nl) | cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301209I1 (nl) | capmatinib of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301003I2 (nl) | Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan | |
| NL300993I2 (nl) | Apalutamide of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301150I2 (nl) | setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301049I1 (nl) | Crisaborale, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301166I2 (nl) | Avacopan of een farmaceutisch aanvaardbaar zout daarvan | |
| NO2020038I1 (no) | Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt | |
| NL301037I2 (nl) | Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan | |
| NL301071I2 (nl) | alpelisib of een farmaceutisch aanvaardbaar zout ervan | |
| NL350108I2 (nl) | Isofetamid of een zout daarvan | |
| NL300886I2 (nl) | baricitinib, of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301261I2 (nl) | Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout. | |
| NL300865I1 (nl) | Eluxadoline of een farmaceutisch aanvaardbaar zout ervan | |
| NL301250I2 (nl) | piflufolastat (18F) of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301042I1 (nl) | Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NO2019027I1 (no) | kobicistat eller et farmasøytisk akseptabelt salt derav | |
| NL300990I2 (nl) | Brigatinib, dan wel een farmaceutisch aanvaardbaar zout daarvan | |
| NO2016016I1 (no) | Lesinurad, eller et farmasøytisk akseptabelt salt derav | |
| NO2018016I2 (no) | Niraparib eller et farmasøytisk akseptabelt salt, stereoisomer eller tautomer derav | |
| NL301021I1 (nl) | talazoparib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout. | |
| NL300946I2 (nl) | Brexpiprazole, desgewenst in de vorm van een zout | |
| NL301177I1 (nl) | tecovirimat of een farmaceutisch aanvaardbaar zout daarvan |